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ABSTRACT
The IUPHAR database is an established online ref-
erence resource for several important classes of
human drug targets and related proteins. As well
as providing recommended nomenclature, the
database integrates information on the chemical,
genetic, functional and pathophysiological pro-
perties of receptors and ion channels, curated and
peer-reviewed from the biomedical literature by a
network of experts. The database now includes
information on 616 gene products from four
superfamilies in human and rodent model organ-
isms: G protein-coupled receptors, voltage- and
ligand-gated ion channels and, in a recent update,
49 nuclear hormone receptors (NHRs). New data
types for NHRs include details on co-regulators,
DNA binding motifs, target genes and 3D structures.
Other recent developments include curation of the
chemical structures of approximately 2000 ligand
molecules, providing electronic descriptors, identi-
fiers, link-outs and calculated molecular properties,
all available via enhanced ligand pages. The
interface now provides intelligent tools for the visu-
alization and exploration of ligand structure-activity
relationships and the structural diversity of
compounds active at each target. The database is
freely available at http://www.iuphar-db.org.
INTRODUCTION
Complementary to the familiar large-scale data banks
holding the outputs of genomics research are many
smaller, highly focused databases, whose remit is the
comprehensive curation of selected subsets of genes
through annotation of historic and emerging biological
literature. Such resources are often created to address
the speciﬁc needs of particular research ﬁelds and
normally rely on the voluntary efforts of interested
experts and a community of scientists. These resources
can provide distilled data tailored to the requirements
of the end user. The need for such facilities will only in-
tensify as the amount and complexity of scientiﬁc data
increases.
In 2009 we reported the development of an
expert-curated database (1) from the International
Union of Basic and Clinical Pharmacology Committee
on Receptor Nomenclature and Drug Classiﬁcation
(NC-IUPHAR, http://www.iuphar.org/nciuphar.html).
The IUPHAR database (IUPHAR-DB, http://www
.iuphar-db.org) displays detailed information on the struc-
ture, function, anatomy, pathophysiology and pharmacol-
ogy of G protein-coupled receptors (GPCRs), voltage-
gated ion channels (VGICs) and ligand-gated ion
channels (LGICs). Members of these protein superfamilies
correspond to the biological targets of at least one-third of
licensed medicinal drugs (2).
The database is a result of the voluntary efforts of over
700 international expert scientists coordinated by
NC-IUPHAR through its network of subcommittees.
The content and curation model of IUPHAR-DB have
already been described (1); here we will focus on
advances in the construction, content and user interface.
We announce the addition of a fourth class of important
drug targets and transcription regulators, the nuclear
hormone receptors (NHRs). Furthermore, we provide
details on improvement to the curation process for
chemical compounds, which has resulted in the ﬁrst
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We also introduce a range of new features that enhance
usability of the database, including redesigned ligand
pages and intelligent tools for structure-based exploration
of ligand–target interactions. We hope these will allow
interested chemists and pharmacologists to rapidly visual-
ize and appreciate the diversity of ligands, their chemical
proﬁles and the structure activity relationships represented
in the data.
CONTENT
In its current release the database contains information on
proteins encoded by 356 GPCR genes, 141 VGIC subunit
genes, 52 LGIC subunit genes and 49 NHR genes in
human, rat and mouse. The database documents 6533
interactions between these proteins and 2715 distinct
ligand molecules. All data included in IUPHAR-DB are
curated from the primary literature by expert subcommit-
tees or individual experts appointed by NC-IUPHAR or
by in-house curators and then reviewed by external
experts. The database currently references 11332 unique
publications, 99% of which are linked to PubMed (http://
www.ncbi.nlm.nih.gov/pubmed). Supplementary Figure
S1 provides charts describing the content of gene
families in IUPHAR-DB.
NEW FEATURES
Nuclear hormone receptors
Recently, the database has expanded to provide the ﬁrst
comprehensive annotation of the literature on the
pharmacology of 49 human NHR gene products and
their rodent orthologues, together with relevant informa-
tion on their structure and function. The information in
IUPHAR-DB complements that available in other online
resources such as the Nuclear Receptor Signaling Atlas
(NURSA) (3), an online resource with curated informa-
tion and experimental data for receptors, ligands and
co-regulators and NureXbase (http://nurexbase.prabi.fr),
a multi-species genomic database with structural informa-
tion for NHRs, complexes and endocrine disruptors.
Unlike the other receptors in IUPHAR-DB, which are
cell surface proteins that transduce extracellular signals by
modulating intracellular concentrations of second messen-
gers or ions, NHRs are intracellular, non-transmembrane
proteins with distinct structural and functional properties
(4). NHRs are transcriptional regulators that exert their
actions by binding to sequence-speciﬁc promoter elements
on target genes. NHR ligands include steroid and thyroid
hormones, metabolites and xenobiotics; many NHRs are
‘orphan’ receptors, for which the endogenous ligands are
still unknown or may not exist.
IUPHAR-DB provides details of recommended nomen-
clature, synonyms used in the literature, structure,
genomic location, physiological function, tissue distribu-
tion, functional assays, biologically signiﬁcant alternative-
ly spliced and RNA-edited variants, the clinical-relevance
of polymorphisms and phenotypes resulting from alter-
ations in gene-expression. Pharmacological information
includes the afﬁnities of selected agonists and antagonists,
such as approved drugs, commonly used experimental
compounds and endogenous ligands. For NHRs,
additional ‘custom’ information is provided, including
details of consensus DNA response elements, co-binding
partners required for DNA binding, co-repressor and
co-activator proteins and the main target genes regulated
by NHRs. Each NHR in IUPHAR-DB is hyperlinked to
the corresponding entries in other relevant databases,
including several of the NCBI Entrez databases (5), the
human, rat and mouse genome databases [HGNC (6),
MGI (7) and RGD (8)] and NURSA. Links to other
databases containing information on drug targets and
their ligands are provided on a ‘Useful Links’ page,
which is regularly updated.
Three-dimensional structures
Structural information about receptors and channels has
been enhanced by the addition of links to experimentally
solved protein structures in the RCSB Protein Data Bank
(RCSB PDB) (9). There is extensive three dimensional
(3D) structural information available on NHRs, so for
each receptor we have selected at least three representative
structures, including, where available, an ‘apo’ structure
(protein with no ligand bound), a protein bound to an
agonist and a protein bound to an antagonist. Details
have been added to the database for the few GPCR,
VGIC and LGIC structures that are known. Database
pages also include dynamic links to complete lists of struc-
tures available in the RCSB PDB for each protein and
from IUPHAR-DB ligands to PDB ligand pages.
Ligand classiﬁcation and structural information
Previously, information on ligand molecules in
IUPHAR-DB was limited to common names and
synonyms and PubChem compound identiﬁers (CIDs)
(10). In 2009 we began an initiative to curate and
classify all ligand molecules in IUPHAR-DB,
incorporating structural speciﬁcation, computational
molecular descriptors and other information. Rigorous
deﬁnition of chemical compounds brings many
advantages to both database developers and users; for
instance knowledge of chemical structure reduces unin-
tended duplication where multiple publications refer to
the same compound under different synonyms or fail to
provide the chemical structure. It is now possible to un-
ambiguously identify compounds in IUPHAR-DB and
use molecular descriptors to search for them in other data-
bases. We have extended the functionality of our in-house
curation tools to enable straightforward curation of
chemical structures.
During the chemical curation process we manually
checked each compound against the primary literature
to ensure that chemical structures were attributed to the
correct compound names, removed over 200 duplicates
and associated each compound with PubChem
CIDs where possible. In all cases we endeavoured to
provide correct isomeric forms; however, we found that
stereomeric information is often omitted in the
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obliged to use the non-isomeric representations for all
cases where enantiomers or diastereomers are not speciﬁed
in the primary assay used; this reﬂects some of the un-
avoidable historical ambiguity seen in pharmacological
data.
About two-thirds of the IUPHAR-DB compounds were
unambiguously identiﬁed in the PubChem compounds
database. Utilizing the PubChem download service we
were able to retrieve 1944 chemical structures in simpliﬁed
molecular input line entry speciﬁcation (SMILES) format
(http://www.daylight.com/dayhtml/doc/theory/theory.
smiles.html). To enable the full and unambiguous identi-
ﬁcation of IUPHAR compounds, each molecular entity is
represented by its common name, a list of synonyms, a
systematic name, unique chemical identiﬁers and several
structural descriptors and formats. The Open Babel
software package (http://openbabel.org/wiki/Main_Page)
was used to unify the format of the retrieved SMILES
strings and create various structural descriptors.
Generated descriptors include two types of SMILES
descriptor, one containing isomeric speciﬁcation of chiral
compounds and a second without chiral or isotopic speci-
ﬁcation, IUPAC International Chemical Identiﬁers
(InChI) and InChI Keys (http://www.iupac.org/inchi).
Systematic IUPAC names and two-dimensional (2D)
images for use on the IUPHAR-DB website were
generated using the NCI/CADD Chemical Identiﬁer
Resolver from the National Cancer Institute (http://
cactus.nci.nih.gov/chemical/structure). Various physico-
chemical properties were calculated using the Chemistry
Development Kit (CDK) (11), including the ﬁve Lipinski
‘drug-likeness’ measures (12): polar surface area (TPSA)
(13), predicted LogP (XLogP) (14), molecular weight,
number of hydrogen bond donors and acceptors. The
number of rotatable bonds is also included because this
can be a useful indication of the compound ﬂexibility and
complexity.
The ﬁnal set of 2715 distinct compounds were then clas-
siﬁed into the following classes: synthetic organic-based
compounds, inorganic molecules (e.g. ions), simple natur-
ally occurring bioactive compounds, natural products,
peptides (both synthetic and naturally occurring) and an
‘other’ class for the few compounds that do not fall into
any of the former categories. Supplementary Figure S1
describes the distribution of IUPHAR-DB ligands into
their classes.
Enhanced ligand pages
Each ligand entry in IUPHAR-DB has a dedicated data
page displaying information about its structural properties
and biological activity (Figure 1). Where available, an
image of the ligand’s 2D structure and physicochemical
properties are displayed. A series of tabs provide access
to further information. A summary tab includes the
ligand’s classiﬁcation, whether it is known to be an
approved drug, the systematic name and other
synonyms. To help users ﬁnd further information on
licensed drugs and experimentally used compounds we
provide links to databases such as DrugBank (15), the
Pharmacogenomics Knowledge Base (PharmGKB) (16)
and Chemical Entities of Biological Interest (ChEBI) (17).
A second tab contains information on the ligand’s
biological activity with tables listing its selectivity at re-
ceptors in IUPHAR-DB and links to the relevant receptor
pages. A third tab displays a reference list and a fourth tab
provides descriptors and download options for the
chemical structure. Another tab provides a display of
any structurally similar compounds that exist in the
database, with lists of their receptor targets and links to
the relevant data pages. A useful feature is the ability to
quickly launch a chemical editor (by clicking on the
ligand’s image or following a link under the ‘Similar com-
pounds’ tab), allowing the structure to be modiﬁed and
used for structure-based searching of the database
(see below for details). Pharmacological data tables on
receptor pages have also been enhanced with structural
information about ligands, which helps users to visualize
the types of compounds that interact with speciﬁc
receptors.
New search tools
In addition to text-based searches of the database content
the search tools now allow receptor and ligand retrieval
by external identiﬁer, such as by protein accession or
DrugBank identiﬁer. Moreover, users are now able to
navigate ligand structure space by drawing a chemical
structure or pasting a SMILES string into a chemical
editor [ChemAxon’s MarvinSketch (https://www
.chemaxon.com/marvin/sketch/index.php) Java applet]
and performing a structure-based query of the database.
The available search methods are substructure, exact,
similarity and SMARTS-pattern (http://www.daylight
.com/dayhtml/doc/theory/theory.smarts.html) matching.
Structure-based searches are powered by Dotmatics’
Pinpoint software (http://www.dotmatics.com/products_
pinpoint.jsp). On the results page users see the structures
of matched compounds and a quick overview of their
receptor targets, with links to ligand and receptor pages
and options to reﬁne the search such as limiting by
molecular weight or polar surface area (Figure 2).
FUTURE PERSPECTIVES
While we have obtained chemical structures for the
majority of small molecule ligands in IUPHAR-DB,
structural information for a majority of the approximately
900 endogenous and synthetically derived peptide ligands
is lacking. Furthermore, the implemented structure-based
search methods are not appropriate for oligopeptides, for
which sequence-based methods may be preferable. In a
future database release we aim to provide primary
sequences and information on the post-translational
modiﬁcation of endogenous peptides and also the amino
acid sequences and chemical modiﬁcations of synthetic
peptides. We also plan to expand the coverage of
IUPHAR-DB to include further protein families and
new data types.
D536 Nucleic AcidsResearch, 2011, Vol.39, Database issueFigure 1. Part of a ligand page showing an image of the 2D structure, calculated physicochemical properties and tables of biological activity at
GPCRs, ion channels and NHRs.
Nucleic Acids Research, 2011,Vol.39, Database issue D537CITING IUPHAR-DB
For a general citation of the resource we recommend
citing this article. For citing speciﬁc receptor pages we
recommend a format similar to the following example:
A. P. Davenport, E. J. Mead. Kisspeptin receptor. Last
modiﬁed on <date>. Accessed on <date>. IUPHAR
database (IUPHAR-DB), http://www.iuphar-db
.org/DATABASE/FamilyMenuForward?familyId=34.
SUPPLEMENTARY DATA
Supplementary Data are available at NAR Online.
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